Drug reference

somapacitan

Human growth hormone analogue · Growth hormone replacement

Human growth hormone analogueGrowth hormone replacement

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

3 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactions

BexaroteneSevereDatabaseDDInter
LevacetylmethadolSevereDatabaseDDInter
LumateperoneSevereDatabaseDDInter

Mechanism

Somapacitan is a human GH analogue designed with an albumin-binding moiety. This moiety extends the half-life and reduces the clearance of somapacitan by allowing reversible binding to endogenous albumin, enabling once-weekly administration.

Indications

Adults with GH deficiency

Dosing

Adult: Typical starting dose is 1.5 mg weekly. This dose is increased in increments of 0.5 to 1.5 mg (weekly dose no higher than 8 mg) until the desired clinical response and serum IGF-1 concentrations are achieved.

Pharmacokinetics

Peak effect

Maximum concentration after initial subcutaneous injection is reached in 4 to 24 h, with steady-state concentrations achieved within 2 weeks.

Half-life

2 to 3 days

Protein binding

greater than 99% bound to plasma proteins

Contraindications

Follows same indications and contraindications for GH in adults (e.g., closed epiphyses for growth promotion, acute critical illness, active malignancy, severe diabetic retinopathy, hypersensitivity).

Side effects

Common

Back and joint painIndigestionSleep disorderDizzinessTonsillitisPeripheral edemaVomitingAdrenal insufficiencyHypertensionIncrease in blood creatine phosphokinaseWeight gainAnemiaArthralgiaDyspepsia